17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Advise patients that EXEMESTANE lowers the level of estrogen in the body. This may lead to reduction in bone mineral density (BMD) over time. The lower the BMD, the greater the risk of osteoporosis and fracture [see Warnings and Precautions (5.1)].
Other Estrogen-Containing Agents
Advise patients that they should not take estrogen-containing agents while they are taking EXEMESTANE as these could interfere with its pharmacologic action [see Warnings and Precautions (5.3)].
Use in Premenopausal Women
Advise patients that EXEMESTANE is not for use for the treatment of breast cancer in premenopausal women [see Warnings and Precautions (5.5)].
Advise pregnant women and females of reproductive potential that exposure during pregnancy or within 1 month prior to conception can result in fetal harm. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.6) and Use in Specific Populations (8.1)].
Advise females of reproductive potential to use effective contraception while taking EXEMESTANE and for 1 month after the last dose [see Use in Specific Populations (8.3)].
Advise women not to breastfeed during treatment with EXEMESTANE and for 1 month after the last dose [see Use in Specific Populations (8.2)].
This product's label may have been updated. For current full prescribing information, please visit www.greenstonellc.com